Disease · MONDO_0003014
rhinitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. rhinitis. Diseases, record MONDO_0003014. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003014
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Approval, for 4 of its 14 drugs, from DailyMed, EMA Human Drugs and TTD
- Open Targets
Drugs14
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CYPROHEPTADINE | CHEMBL516 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| DEXCHLORPHENIRAMINE MALEATE | CHEMBL1200927 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| FLUNISOLIDE | CHEMBL1512 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| OMALIZUMAB | CHEMBL1201589 | Antibody | Approval | EMA Human Drugs | 1 | 0 | 0 | Drugs and targets |
| TRIAMCINOLONE ACETONIDE | CHEMBL1504 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ANDOLAST | CHEMBL119549 | Small molecule | Phase 3 | TTD | 1 | 0 | 0 | Drugs and targets |
| SB-705498 | CHEMBL207433 | Small molecule | Phase 2 | TTD | 2 | 1 | 1 | Drugs and targets |
| FLUTICASONE FUROATE | CHEMBL1676 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AWD-12-281 | CHEMBL3218685 | Small molecule | Phase 2 | TTD | 1 | 0 | 0 | Drugs and targets |
| EFLETIRIZINE | CHEMBL2104290 | Small molecule | Phase 2 | TTD | 1 | 0 | 0 | Drugs and targets |
1 to 10 of 14
See all 14 drugsTargets5
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 3 | Glucocorticoid receptor agonist | Approval | https://conductscience.org/library/genes/2908 | Drugs and targets |
| HRH1 | Histamine H1 receptor | 2 | Histamine H1 receptor antagonist | Approval | https://conductscience.org/library/genes/3269 | Drugs and targets |
| IGHE | Immunoglobulin heavy constant epsilon | 1 | Ig epsilon chain C region inhibitor | Approval | https://conductscience.org/library/genes/3497 | Drugs and targets |
| KCNMA1 | Calcium-activated potassium channel subunit alpha-1 | 1 | Calcium-activated potassium channel subunit alpha-1 activator | Phase 3 | https://conductscience.org/library/genes/3778 | Drugs and targets |
| TRPV1 | Transient receptor potential cation channel subfamily V member 1 | 1 | Vanilloid receptor antagonist | Phase 2 | https://conductscience.org/library/genes/7442 | Drugs and targets |
Trials5
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00730756 | A Pilot Study In Adults And Adolescents With Irritant (Non-Allergic) Rhinitis | Phase 2 | 102 | 2009-11-25 | Rhinitis, Allergic, Perennial | FLUTICASONE FUROATE | Its record names the disease | ClinicalTrials.gov |
| NCT00344942 | Efficacy and Safety Study of Nasacort in Chronic Non Allergic and Non Infectious Rhinitis in Adults | Phase 3 | 77 | Rhinitis | TRIAMCINOLONE ACETONIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT00731250 | A Study To Assess The Effect Of SB-705498 In A Capsaicin Challenge Model | Phase 1 | 45 | Rhinitis | SB-705498 | Its record names the disease | ClinicalTrials.gov | |
| NCT02593851 | A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection | Phase 1 | 45 | Respiratory Syncytial Virus Infections, Virus Diseases | RILEMATOVIR | Its record names the disease | ClinicalTrials.gov | |
| NCT00281307 | Treatment of Rhinitis With Intranasal Vitamin E | Not applicable | 10 | Rhinitis | ALPHA-TOCOPHEROL | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| FFNS 110 mcg vs Placebo: serious adverse events | 1 of 53 | 0 of 49 | 102 | NCT00730756 |
Source Trial comparisons
Papers from its trials1
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it |
|---|---|---|
| 32201897 | DERIVED | 1 |
Source PubMed
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0003014
GET https://conductscience.org/api/diseases/v1/MONDO_0003014/drugs